阿帕替尼治疗化疗失败的进展期胃癌的疗效及安全性  

Efficacy and safety of apatinib treatment for advanced gastric cancer after chemotherapy resistance

作　　者：樊翠珍[1] 张晓静 初玉平[1] 安广宇[1] FAN Cuizhen;ZHANG Xiaojing;CHU Yuping;AN Guangyu(Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China)

机构地区：[1]首都医科大学附属北京朝阳医院肿瘤科,北京100020

出　　处：《肿瘤》2018年第4期356-361,共6页Tumor

摘　　要：目的 :观察阿帕替尼单药治疗化疗失败的晚期胃癌的疗效及不良反应。方法 :31例晚期胃癌患者口服阿帕替尼250 mg/d,28 d为1个治疗周期。每2个周期复查CT或MRI,评价近期疗效和不良反应。随访观察疾病进展时间(time to progression,TTP)和总生存(overall survival,OS)。结果 :31例晚期胃癌患者中,无完全缓解患者,部分缓解患者7例(22.6%),疾病稳定10例(32.3%),疾病进展14例(45.2%),疾病控制率为54.8%,客观缓解率为22.6%,临床获益率为54.8%。中位TTP为4.0个月(95%可信区间:3.2~4.8个月),中位生存时间为5.3个月(95%可信区间:3.2~7.4个月)。常见不良反应为高血压、手足皮肤反应、乏力、蛋白尿和肝功能损害。结论 :阿帕替尼单药口服对晚期化疗失败的胃癌患者治疗有效。Objective： To observe the clinical efficacy and adverse reactions of apatinib in advanced gastric cancer after routine chemotherapy.Methods： Thirty-one patients cancer and had a deterioration with unrespectable stage Ⅳ gastric or recurrence after at least 2 cycles of chemotherapy with thymidine phosphorylase-based regimen, were recruited in this study. The patients were given with 500-250mg of apatinib once daily till disease progression. A chest and abdomen CT or MRI scan was taken every 2 cycles for a response assessment.Results： Among the 31 patients, no one achieved complete response, 7 patients （22.6%） had partial response, 17 patients （32.3%） had stable disease; the disease control rates was 54.8%. The median time to progression was 4.0 months [95% confidence interval （CI）： 3.2-4.8]. The median survival time was 5.3 months （95% CI： 3.2-7.4）. The main adverse reactions were hypertension, hand foot syndrome, diarrhea,fatigue, proteinuria and liver function damage.Conclusion： Apatinib can obtain good clinical effect in treatment of advanced gastric cancer after chemotherapy resistant.

关 键 词：胃肿瘤 阿帕替尼 靶向治疗 化疗耐药 

分 类 号：R735.2[医药卫生—肿瘤]